Your browser doesn't support javascript.
loading
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance.
Geraud, Arthur; Gougis, Paul; Vozy, Aurore; Anquetil, Celine; Allenbach, Yves; Romano, Emanuela; Funck-Brentano, Elisa; Moslehi, Javid J; Johnson, Douglas B; Salem, Joe-Elie.
Afiliação
  • Geraud A; Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP² Galilée, UNICO-GRECO Cardio-oncology Program, and Department of Pharmacology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, F-75013 Paris, France; email: joe-elie.salem@aphp.fr.
  • Gougis P; Department of Drug Development (DITEP), Gustave Roussy, 94805 Villejuif, France.
  • Vozy A; Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP² Galilée, UNICO-GRECO Cardio-oncology Program, and Department of Pharmacology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, F-75013 Paris, France; email: joe-elie.salem@aphp.fr.
  • Anquetil C; Sorbonne Université, INSERM, CIC-1901 Paris-Est, CLIP² Galilée, UNICO-GRECO Cardio-oncology Program, and Department of Pharmacology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, F-75013 Paris, France; email: joe-elie.salem@aphp.fr.
  • Allenbach Y; Sorbonne Université, INSERM, Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, F-75013 Paris, France.
  • Romano E; Sorbonne Université, INSERM, Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, F-75013 Paris, France.
  • Funck-Brentano E; Center for Cancer Immunotherapy, INSERM U932, Institut Curie, 75248 Paris Cedex 05, France.
  • Moslehi JJ; Department of General and Oncologic Dermatology, Ambroise-Paré Hospital, AP-HP, EA 4340, Université Paris-Saclay, 92100 Boulogne-Billancourt, France.
  • Johnson DB; Department of Medicine, Cardio-Oncology Program, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
  • Salem JE; Department of Medicine, Cardio-Oncology Program, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
Annu Rev Pharmacol Toxicol ; 61: 85-112, 2021 01 06.
Article em En | MEDLINE | ID: mdl-32871087
T cells have a central role in immune system balance. When activated, they may lead to autoimmune diseases. When too anergic, they contribute to infection spread and cancer proliferation. Immune checkpoint proteins regulate T cell function, including cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) and its ligand (PD-L1). These nodes of self-tolerance may be exploited pharmacologically to downregulate (CTLA-4 agonists) and activate [CTLA-4 and PD-1/PD-L1 antagonists, also called immune checkpoint inhibitors (ICIs)] the immune system.CTLA-4 agonists are used to treat rheumatologic immune disorders and graft rejection. CTLA-4, PD-1, and PD-L1 antagonists are approved for multiple cancer types and are being investigated for chronic viral infections. Notably, ICIs may be associated with immune-related adverse events (irAEs), which can be highly morbid or fatal. CTLA-4 agonism has been a promising method to reverse such life-threatening irAEs. Herein, we review the clinical pharmacology of these immune checkpoint agents with a focus on their interplay in human diseases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Antineoplásicos Imunológicos / Neoplasias Limite: Humans Idioma: En Revista: Annu Rev Pharmacol Toxicol Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Antineoplásicos Imunológicos / Neoplasias Limite: Humans Idioma: En Revista: Annu Rev Pharmacol Toxicol Ano de publicação: 2021 Tipo de documento: Article